Lixte pauses NKI/Oncode collaboration until Phase 1b trial starts; budget cut to €100K

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Amendment 3 pauses research activities under the development collaboration with NKI and Oncode Institute.
Collaboration resumes upon first patient dosing in Phase 1b trial combining LB-100 with a WEE1 inhibitor in metastatic colorectal cancer.
Termination date revised to one year from first patient dosing; annual budget reduced from €250,000 to €100,000.
Parties will study translational data from patient samples in NKI clinical trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.